Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Telavancin
Drug ID BADD_D02143
Description Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.
Indications and Usage For the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria like methicillin-susceptible or -resistant Staphylococcus aureus, vancomycin-susceptible Enterococcus faecalis, and Streptococcus pyogenes, Streptococcus agalactiae, or Streptococcus anginosus group. Also for the treatment of adult patients with hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP), known or suspected to be caused by susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant S. aureus).
Marketing Status approved
ATC Code J01XA03
DrugBank ID DB06402
KEGG ID D06057
MeSH ID C487637
PubChem ID 3081362
TTD Drug ID D0B9JO
NDC Product Code 71124-0005
UNII XK134822Z0
Synonyms telavancin | TD 6424 | TD6424 | TD-6424 | Vibativ | telavancin hydrochloride
Chemical Information
Molecular Formula C80H106Cl2N11O27P
CAS Registry Number 372151-71-8
SMILES CCCCCCCCCCNCCNC1(CC(OC(C1O)C)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)N C(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl) O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thrombocytosis01.08.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urine abnormality20.02.01.013--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Ventricular extrasystoles02.03.04.007--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Infusion site erythema23.03.06.016; 12.07.05.009; 08.02.05.008--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Infusion site pain08.02.05.014; 12.07.05.002--Not Available
Infusion site reaction12.07.05.006; 08.02.05.005--Not Available
Urine odour abnormal20.02.01.020--Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.003--Not Available
Clostridium colitis11.02.02.005; 07.19.01.011--Not Available
Angiopathy24.03.02.007--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages